Anti-VEGF therapy for choroidal neovascularization secondary to Birdshot chorioretinopathy

Poster Details

First Author: P.Plaza-Ramos SPAIN

Co Author(s):    H. Heras-Mulero   E. Compains Silva   A. Zubicoa Eneriz   C. Abascal-Azanza   L. Tabuenca Del Barrio   M. Mozo Cuadrado              

Abstract Details


Birdshot chorioretinopathy is a bilateral, autoimmune posterior uveitis with a strong association with HLA-A29. It is a chronic and progressive disease which has a significant potential for irreversible tissue damage and visual loss. Choroidal neovascular membrane (CNV) represents a rare complication in Birdshot chorioretinopathy, reported in 6% of cases.


We report a case to highlight this phenomenon.


43-year-old man diagnosed of BCR in 2006 treated with corticoids and azathioprine. He was correctly controlled with this treatment and his visual acuity was 20/20 since the beginning. Since 2013 he was without treatment and stable. In August 2016, he arrived to emergencies with blurry vision, metamorphopsias and a visual acuity of 20/40. He was diagnosed of a CNV confirmed with optical coherence tomography and fluorescein angiography.


He was treated with intravitreous ranibizumab and in the following reviews no other treatment was needed. His actual visual acuity is 20/20.


We want to remark the difference between a reactivation of the disease and a vascular complication, even though, the understanding of the pathogenesis of this type of membrane still poor. Inflammation play an important role in this kind of membranes. Although retinal neovascularization may develop in the absence of capillary ischaemia in patients with posterior uveitis, anti-VEGF alone can also respond to CNV. Proper studies will be needed to establish therapeutic regimes and long term outcomes.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy